Ulcerative Colitis Flare-Ups: Educating Patients

Aimee Simone, Assistant Editor
Published Online: Monday, June 24, 2013
Follow Pharmacy_Times:
Although patients with ulcerative colitis recognize flare-up symptoms, a new study published in the April 2013 issue of Gastroenterology Research, reports that many patients do not consider these symptoms as a reason to visit their physician.

The researchers surveyed 260 patients diagnosed with ulcerative colitis from the Crohn’s and Colitis Foundation of Japan to determine the gap between symptom recognition and physician visits. Participants were asked to describe symptoms of flare-ups and to describe symptoms that required a doctor visit. Gaps were defined if patients listed critical symptoms, aggravated symptoms, or persistent symptoms as symptoms requiring a physician visit. The researchers also analyzed participants’ responses to determine whether patients delayed physician visits when they experienced flare-up symptoms. Obvious delay was determined if a patient’s description of flare-up symptoms included critical symptoms.

A gap was found in approximately 56% of patients. Obvious delay was determined in almost 30% of participants. The researchers also found that about half of patients would consider consulting with their physician if their symptoms became worse while the other half would want to visit their physician immediately.

The authors conclude that patients can accurately recognize flare-up symptoms, yet half of the participants would not consider them as a sign to visit their physician. They suggest that health care professionals educate patients in order to improve their conditions.

Related Articles
Adults aged 50 years or older who feel comfortable about aging are more likely to seek preventive health care services.
As nearly one-third of patients with gastroesophageal reflux disease are partial responders to proton pump inhibitors (PPIs), health care professionals could benefit from reliable methods that predict who will respond to PPIs and who will not.
Patients with irritable bowel syndrome cannot block pain signals from the gut as easily as those without the gastrointestinal condition.
The drugmaker will no longer pursue FDA approval of its dual daclatasvir and asunaprevir treatment for patients with hepatitis C virus genotype 1b.
Latest Issues
$auto_registration$